Neutralizing intraspinal nerve growth factor with a trkA-IgG fusion protein blocks the development of autonomic dysreflexia in a clip-compression model of spinal cord injury.
Increased intraspinal nerve growth factor (NGF) after spinal cord injury (SCI) is detrimental to the autonomic nervous system. Autonomic dysreflexia is a debilitating condition characterized by episodic hypertension, intense headache, and sweating. Experimentally, it is associated with aberrant primary afferent sprouting in the dorsal horn that is nerve growth factor (NGF)-dependent. Therapeutic strategies that neutralize NGF may ameliorate initial apoptotic cellular responses to the injury and aberrant afferent plasticity that occurs weeks after the injury. Subsequently, the development of autonomic disorders may be suppressed. We constructed a protein including the extracellular portion of trkA fused to the Fc portion of human IgG and expressed it using a baculovirus system. Binding of our trkA-IgG fusion protein was specific for NGF with a K(d) = 4.26 x 10(-11) M and blocked NGF-dependent neuritogenesis in PC-12 cells. We hypothesized that binding of NGF in the injured cord by our trkA-IgG fusion protein would diminish autonomic dysreflexia. Severe, high thoracic SCI was induced with clip compression and the rats were treated with intrathecal infusions (4 microg/day) of trkA-IgG or control IgG. At 14 days post-SCI, the magnitude of autonomic dysreflexia was assessed. Colon distension increased mean arterial pressure (MAP) in control rats by 46 +/- 2 from 96 +/- 5 mmHg. In contrast, MAP of rats treated with trkA-IgG increased by only 30 +/- 2 mmHg. Likewise, the MAP response to cutaneous stimulation was also reduced in rats treated with trkA-IgG (20 +/- 1 vs. 29 +/- 2). In contrast, trkA-IgG treatment had no effect on heart rate responses during colon distension or cutaneous stimulation. These results indicate that treatment with trkA-IgG to block NGF suppresses the development of autonomic dysreflexia after a clinically relevant spinal cord injury.
Marsh
Daniel R
DR
Spinal Cord Injury Laboratory, Biotherapeutics Group, John P Robarts Research Institute, University of Western Ontario, London, Ontario, Canada. dmarsh@rri.on.ca
Wong
Sharon T
ST
Meakin
Susan O
SO
MacDonald
James I S
JI
Hamilton
Eilis F
EF
Weaver
Lynne C
LC
D000818:Animals; D020211:Autonomic Dysreflexia / Q000378:metabolism / Q000503:physiopathology / Q000517:prevention & control*; D016367:Baculoviridae / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects; D002352:Carrier Proteins / Q000494:pharmacology / Q000627:therapeutic use*; D002478:Cells, Cultured; D003106:Colon / Q000294:innervation / Q000502:physiology; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D008565:Membrane Proteins / Q000494:pharmacology / Q000627:therapeutic use*; D020932:Nerve Growth Factor / Q000037:antagonists & inhibitors* / Q000276:immunology; D016716:PC12 Cells / Q000187:drug effects; D010812:Physical Stimulation; D051381:Rats; D017208:Rats, Wistar; D020917:Receptor, trkA; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis / Q000494:pharmacology / Q000627:therapeutic use; D013117:Spinal Cord Compression / Q000150:complications / Q000503:physiopathology*
D002352:Carrier Proteins; D007074:Immunoglobulin G; D008565:Membrane Proteins; D011993:Recombinant Fusion Proteins; D020932:Nerve Growth Factor; D020917:Receptor, trkA